ArticleFrontiers in pharmacology2024

Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents.

Xuanhong Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.